AU2008241013B2 - Titration of tapentadol - Google Patents

Titration of tapentadol Download PDF

Info

Publication number
AU2008241013B2
AU2008241013B2 AU2008241013A AU2008241013A AU2008241013B2 AU 2008241013 B2 AU2008241013 B2 AU 2008241013B2 AU 2008241013 A AU2008241013 A AU 2008241013A AU 2008241013 A AU2008241013 A AU 2008241013A AU 2008241013 B2 AU2008241013 B2 AU 2008241013B2
Authority
AU
Australia
Prior art keywords
dose
administration
tapentadol
optional
interval
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008241013A
Other languages
English (en)
Other versions
AU2008241013A1 (en
Inventor
Claudia Lange
Ferdinand Rombout
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Chemie Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38123877&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2008241013(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal GmbH, Chemie Gruenenthal GmbH filed Critical Gruenenthal GmbH
Publication of AU2008241013A1 publication Critical patent/AU2008241013A1/en
Application granted granted Critical
Publication of AU2008241013B2 publication Critical patent/AU2008241013B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Adhesive Tapes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2008241013A 2007-04-23 2008-04-21 Titration of tapentadol Active AU2008241013B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07008218A EP1985292A1 (en) 2007-04-23 2007-04-23 Titration of tapentadol
EP07008218.5 2007-04-23
PCT/EP2008/003178 WO2008128740A1 (en) 2007-04-23 2008-04-21 Titration of tapentadol

Publications (2)

Publication Number Publication Date
AU2008241013A1 AU2008241013A1 (en) 2008-10-30
AU2008241013B2 true AU2008241013B2 (en) 2013-06-20

Family

ID=38123877

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008241013A Active AU2008241013B2 (en) 2007-04-23 2008-04-21 Titration of tapentadol

Country Status (21)

Country Link
US (4) US20090012180A1 (https=)
EP (5) EP1985292A1 (https=)
JP (4) JP5933176B2 (https=)
KR (3) KR20100017267A (https=)
CN (1) CN101730530B (https=)
AT (1) ATE534378T1 (https=)
AU (1) AU2008241013B2 (https=)
CA (1) CA2683786C (https=)
CY (1) CY1112320T1 (https=)
DK (1) DK2148670T3 (https=)
ES (1) ES2378255T3 (https=)
HR (1) HRP20120147T1 (https=)
IL (1) IL201479A (https=)
MX (1) MX2009011444A (https=)
NZ (1) NZ580415A (https=)
PL (1) PL2148670T3 (https=)
PT (1) PT2148670E (https=)
RU (1) RU2472497C2 (https=)
SI (1) SI2148670T1 (https=)
WO (1) WO2008128740A1 (https=)
ZA (1) ZA200907355B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
BRPI0921725A2 (pt) * 2008-10-30 2016-01-05 Grüenthal GmbH formas de dosagem potentes do tapentadol
US8870876B2 (en) * 2009-02-13 2014-10-28 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8277459B2 (en) 2009-09-25 2012-10-02 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
US8652141B2 (en) 2010-01-21 2014-02-18 Tarsus Medical Inc. Methods and devices for treating hallux valgus
EP2566461A2 (de) * 2010-05-05 2013-03-13 Ratiopharm GmbH Festes tapentadol in nicht-kristalliner form
US8696719B2 (en) 2010-06-03 2014-04-15 Tarsus Medical Inc. Methods and devices for treating hallux valgus
PL2588093T3 (pl) * 2010-06-30 2017-07-31 Grünenthal GmbH Tapentadol do zastosowania w leczeniu zespołu jelita drażliwego
EP3597628A1 (en) * 2010-07-23 2020-01-22 Grünenthal GmbH Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
CN101948397A (zh) * 2010-09-07 2011-01-19 天津泰普药品科技发展有限公司 镇痛药他喷他多重要中间体的制备方法
CA2828635C (en) * 2011-03-04 2020-01-14 Grunenthal Gmbh Parenteral administration of tapentadol
KR101946790B1 (ko) 2011-03-04 2019-02-13 그뤼넨탈 게엠베하 경구 투여를 위한 타펜타돌의 수성 약제학적 제형
RS56692B1 (sr) 2011-03-04 2018-03-30 Gruenenthal Gmbh Polučvrsta vodena farmaceutska kompozicija koja sadrži tapentadol
US20120309840A1 (en) * 2011-04-05 2012-12-06 Gruenenthal Gmbh Treatment of Pain Associated with Trigeminal Neuralgia
RS58064B1 (sr) 2011-04-05 2019-02-28 Gruenenthal Gmbh Tapentadol za sprečavanje hronifikacije bola
LT3272343T (lt) 2011-04-29 2020-05-11 Grünenthal GmbH Tapentadolis, skirtas depresijos ir nerimo prevencijai ir gydymui
ES2681952T3 (es) * 2013-03-15 2018-09-17 SpecGx LLC Forma farmacéutica sólida disuasoria del abuso de liberación inmediata con puntaje funcional
EP2845625A1 (en) * 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
EP3273953B1 (en) 2015-03-27 2019-01-02 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
ES2869981T3 (es) * 2015-05-26 2021-10-26 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Composiciones para su uso en el tratamiento de la enfermedad de parkinson y trastornos relacionados
JP7373904B2 (ja) * 2016-02-29 2023-11-06 パーク・セラピューティクス・インコーポレイテッド セブラノパドールの滴定
CN109996533A (zh) 2016-09-23 2019-07-09 格吕伦塔尔有限公司 用于肠胃外施用他喷他多的稳定制剂
ES3010208T3 (en) 2020-03-16 2025-04-01 Gruenenthal Gmbh Scored tablet comprising tapentadol
WO2022194941A1 (en) * 2021-03-17 2022-09-22 Actelion Pharmaceuticals Ltd Pharmaceutical dosage system
WO2022234076A1 (en) * 2021-05-07 2022-11-10 Grünenthal GmbH Tapentadol for treating neuropathic pain in covid-19 patients

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050058706A1 (en) * 2001-10-24 2005-03-17 Grunenthal Gmbh Delayed release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
JPS6327805A (ja) 1986-07-21 1988-02-05 Sumitomo Electric Ind Ltd 光フアイバの接続用部材及びそれを用いた接続方法
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6339105B1 (en) * 1999-10-12 2002-01-15 Ortho-Mcneil Pharmaceutical, Inc. Analgesic regimen
AU2003297073A1 (en) 2002-12-13 2004-07-09 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
US7413749B2 (en) 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
DE102007019417A1 (de) * 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050058706A1 (en) * 2001-10-24 2005-03-17 Grunenthal Gmbh Delayed release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol

Also Published As

Publication number Publication date
CY1112320T1 (el) 2015-12-09
ZA200907355B (en) 2010-08-25
IL201479A (en) 2016-04-21
EP3143993A1 (en) 2017-03-22
IL201479A0 (en) 2010-05-31
WO2008128740A1 (en) 2008-10-30
PT2148670E (pt) 2012-01-24
JP2016128468A (ja) 2016-07-14
JP2018030864A (ja) 2018-03-01
EP2148670A1 (en) 2010-02-03
AU2008241013A1 (en) 2008-10-30
DK2148670T3 (da) 2012-03-12
ATE534378T1 (de) 2011-12-15
EP2422778A1 (en) 2012-02-29
US20090012180A1 (en) 2009-01-08
WO2008128740A8 (en) 2010-06-17
US11344512B2 (en) 2022-05-31
KR20100017267A (ko) 2010-02-16
KR20150027840A (ko) 2015-03-12
HK1140940A1 (en) 2010-10-29
CN101730530A (zh) 2010-06-09
SI2148670T1 (sl) 2012-03-30
NZ580415A (en) 2012-04-27
PL2148670T3 (pl) 2012-04-30
US20170079938A1 (en) 2017-03-23
KR102078999B1 (ko) 2020-02-19
JP2010531296A (ja) 2010-09-24
EP3603630A1 (en) 2020-02-05
US20160074342A1 (en) 2016-03-17
EP2148670B1 (en) 2011-11-23
KR20180004839A (ko) 2018-01-12
JP5933176B2 (ja) 2016-06-08
ES2378255T3 (es) 2012-04-10
CN101730530B (zh) 2013-10-23
CA2683786A1 (en) 2008-10-30
JP2019131598A (ja) 2019-08-08
RU2009142940A (ru) 2011-05-27
EP1985292A1 (en) 2008-10-29
US20190290603A1 (en) 2019-09-26
HRP20120147T1 (hr) 2012-03-31
CA2683786C (en) 2021-10-26
RU2472497C2 (ru) 2013-01-20
MX2009011444A (es) 2009-11-05

Similar Documents

Publication Publication Date Title
US11344512B2 (en) Titration of tapentadol
US20200061003A1 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
LT3664B (en) Sustained release drug formation containing a tramadol salt
WO2008156749A1 (en) Combination therapy for depression
JP2010539118A (ja) 蝸牛性耳鳴の治療用１−アミノ−アルキルシクロヘキサン誘導体
US10500170B2 (en) Composition and method for treating neurological disease
US20190247330A1 (en) Composition and method for treating neurological disease
US11833121B2 (en) Composition and method for treating neurological disease
HK1233916A1 (en) Titration of tapentadol
HK1140940B (en) Titration of tapentadol
US20080058345A1 (en) Combination Therapy with Mecamylamine for the Treatment of Mood Disorders

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
ON Decision of a delegate or deputy of the commissioner of patents (result of patent office hearing)

Free format text: (2026) APO 9: DECISION: CLAIMS 1, 2, 6, 8-11, 13-34, 38 AND 40-42 LACK NOVELTY AND INVENTIVE STEP AND CLAIM 12 LACKS AN INVENTIVE STEP. CLAIMS 7 AND 39 HAVE BEEN FOUND TO BE NOVEL AND INVENTIVE. I CONSIDER IT APPROPRIATE FOR THE PATENTEE TO BE PROVIDED WITH AN OPPORTUNITY TO PURSUE PATENTABLE CLAIMS VIA FURTHER AMENDMENT. THE PATENTEE HAS A PERIOD OFTWO (2) MONTHS TO PROVIDE FURTHER AMENDMENTS BEFORE RE-EXAMINATION WILL RECOMMENCE ON THE NEWLY INTRODUCED CLAIMS 3-5 AND 35-37. ABSENT FURTHER AMENDMENTS WITHIN THIS TIME THE PATENT WILL BE REVOKED.

Effective date: 20260316